FDA regulatory expert
Expert class library · Mass tort and product liability · Either side
Explains the FDA approval, labeling, and post-market safety framework for drugs and devices and whether a manufacturer met those regulatory duties. Usually a former agency reviewer or industry regulatory professional, whose testimony is admitted on the regulatory scheme and label adequacy but often trimmed when it strays into causation, intent, or the agency's state of mind.
Ask this expertPreview
A preview of this class of expert, built from the public rulings on this page. Ask how the testimony is built, attacked or defended. 20 questions free with a firm email.
Questions this testimony turns on
- What did FDA regulations require of the manufacturer for labeling, adverse event reporting, and post-market safety?
- Did the manufacturer have reasonable evidence of a causal association that required a label change?
- Was the label adequate from a regulatory perspective, and could the company have changed it unilaterally?
- Did the company comply with its pharmacovigilance and reporting obligations?
Methods
- Regulatory history review
- Labeling change analysis
- Adverse event and pharmacovigilance review
- Industry regulatory practice
How the testimony is attacked
- Straying into medical causation. Defendants argue a regulatory expert cannot testify that the product caused the injury. In Christiansen v. Wright Medical the court excluded the plaintiff's regulatory expert's statements about the plaintiff's metallosis because she was retained for regulatory compliance and had no reliable basis to opine on causation.
- Using notice to smuggle in causation. Opponents argue the expert recasts causation opinions as what should have put the company on notice. In Jones v. Novartis the court barred the regulatory expert from using notice to circumvent the causation ruling and from opining on other drugs and different injuries.
- Narrative and legal conclusions. Defendants argue the expert merely narrates company documents and tells the jury the company violated the law. The Mirena court held that regulatory testimony on the reasonableness of a manufacturer's conduct within the complex FDA framework is helpful, and rejected the argument that the expert could not testify about compliance.
- Speculation about the FDA's state of mind. Both sides attack testimony predicting what the agency would have done or thought. The Mirena court treated speculation about the FDA's state of mind in hypothetical situations as improper, while allowing testimony grounded in the documentary record.
- Daubert factors do not fit. Challengers argue the opinions fail testing, error rate, and peer review. The Mirena and Jones courts held that a non-scientific regulatory opinion is judged by the expert's agency training and experience applied to the record, not the scientific Daubert factors.
What the public record shows
Courts have filed at least 12 opinions since 2015 that discuss this class of testimony and cite Daubert or Rule 702, as of October 2, 2026. Three that show how courts handle this class of testimony:
| Outcome | Case | Court | Year | Why |
|---|---|---|---|---|
| Limited | Christiansen v. Wright Medical Technology Inc.127 F. Supp. 3d 1306 | N.D. Ga. | 2015 | The court excluded the plaintiff's FDA regulatory expert's opinions about the plaintiff's metallosis and its link to the implant failure, because she was retained only on regulatory compliance and lacked a basis to address causation. |
| Limited | Jones v. Novartis Pharmaceuticals Corp.235 F. Supp. 3d 1244 | N.D. Ala. | 2017 | The court accepted the plaintiff's regulatory expert's agency-based methodology as helpful on FDA regulations but barred her from causation opinions, from using notice to evade that ruling, and from testimony about other drugs and injuries. |
| Admitted | In re Mirena IUD Products Liability Litigation169 F. Supp. 3d 396 | S.D.N.Y. | 2016 | The court largely admitted both sides' regulatory experts to testify on the FDA framework, the manufacturer's regulatory compliance, and the adequacy of the label, while trimming specific opinions. |
Each case links to the free opinion text on CourtListener.
In federal court: amended Rule 702
In federal court, since December 1, 2023, Rule 702 says expressly that the party offering an expert must show the court it is more likely than not that the testimony meets each requirement: that it rests on sufficient facts or data, uses reliable methods, and reflects a reliable application of those methods to the case. Questions about the basis of an opinion are no longer automatically matters of weight for the jury. For how the circuits have applied the amendment, see the Rule 702 tracker, which follows each court of appeals; for what that means for preparing or attacking this class of expert, see the guide on amended Rule 702.
Related classes
Guides
Simulating this class on a matter
Supreme Mind simulates a class of expert, never a named individual, on your fact pattern and returns the likely opinion, the ranked cross-examination weaknesses, the Rule 702 attack surface and what it means for settlement. Read how it works, or book a demo.
Updated October 2, 2026. How this page is built: rulings are found by searching court opinions on CourtListener. The summaries are written by AI working from the full text of each opinion, and every citation and link is checked automatically. Outcomes are labelled by what the court did with the expert’s testimony. No individual expert is named. This page summarises public decisions for orientation and is not legal advice; read the opinion before relying on any ruling. Spotted an error? Tell us.